Rachel L Randell1, Ashley V Adams2, Heather Van Mater3. 1. Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina. Electronic address: rachel.randell@duke.edu. 2. Duke University School of Medicine, Durham, North Carolina. 3. Division of Pediatric Rheumatology, Department of Pediatrics, Duke University, Durham, North Carolina.
Abstract
BACKGROUND: Autoimmune encephalitis can result in significant neurological and psychiatric morbidity and mortality in patients of all ages and often does not respond to standard therapies. Recent reports suggest efficacy of tocilizumab, a monoclonal antibody against interleukin 6, in refractory autoimmune encephalitis. RESULTS: We describe three children with refractory autoimmune encephalitis who experienced a robust, immediate clinical response following treatment with tocilizumab. CONCLUSION: These findings support the efficacy and short-term safety of tocilizumab as a third-line treatment for refractory autoimmune encephalitis in children.
BACKGROUND:Autoimmune encephalitis can result in significant neurological and psychiatric morbidity and mortality in patients of all ages and often does not respond to standard therapies. Recent reports suggest efficacy of tocilizumab, a monoclonal antibody against interleukin 6, in refractory autoimmune encephalitis. RESULTS: We describe three children with refractory autoimmune encephalitis who experienced a robust, immediate clinical response following treatment with tocilizumab. CONCLUSION: These findings support the efficacy and short-term safety of tocilizumab as a third-line treatment for refractory autoimmune encephalitis in children.
Authors: Deepti Pilli; Alicia Zou; Ruebena Dawes; Joseph A Lopez; Fiona Tea; Ganesha Liyanage; Fiona Xz Lee; Vera Merheb; Samuel D Houston; Aleha Pillay; Hannah F Jones; Sudarshini Ramanathan; Shekeeb Mohammad; Anthony D Kelleher; Stephen I Alexander; Russell C Dale; Fabienne Brilot Journal: Clin Transl Immunology Date: 2020-12-17
Authors: GenaLynne C Mooneyham; Vladimir Ferrafiat; Erin Stolte; D Catherine Fuchs; David Cohen Journal: Front Psychiatry Date: 2021-03-29 Impact factor: 4.157
Authors: Julia Shekunov; Caren J Blacker; Jennifer L Vande Voort; Jan-Mendelt Tillema; Paul E Croarkin; Magdalena Romanowicz Journal: BMC Neurol Date: 2020-02-03 Impact factor: 2.474